Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug;8(4):101591.
doi: 10.1016/j.esmoop.2023.101591. Epub 2023 Jun 30.

Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine

D Bhamidipati  1 , V Subbiah  2
Affiliations
Editorial

Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine

D Bhamidipati et al. ESMO Open. 2023 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Incidence of KRASG12Cacross tumor histologies. The figure displays the estimated incidence of KRASG12C across various tumor histologies based on genomic sequencing data from large datasets.
See this image and copyright information in PMC

Comment on

  • Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.
    Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, Barve M, Velastegui K, Yan X, Shetty A, Der-Torossian H, Pant S. Bekaii-Saab TS, et al. J Clin Oncol. 2023 Sep 1;41(25):4097-4106. doi: 10.1200/JCO.23.00434. Epub 2023 Apr 26. J Clin Oncol. 2023. PMID: 37099736 Free PMC article.

References

    1. Marcus L., Lemery S.J., Keegan P., Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–3758. - PubMed
    1. Marcus L., Fashoyin-Aje L.A., Donoghue M., et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden–high solid tumors. Clin Cancer Res. 2021;27(17):4685–4689. - PMC - PubMed
    1. Gouda M.A., Nelson B.E., Buschhorn L., Wahida A., Subbiah V. Tumor-agnostic precision medicine from the AACR GENIE database: clinical implications. Clin Cancer Res. 2023 doi: 10.1158/1078-0432.CCR-23-0090. - DOI - PMC - PubMed
    1. Subbiah V., Wolf J., Konda B., et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022;23(10):1261–1273. - PMC - PubMed
    1. Subbiah V., Kreitman R.J., Wainberg Z.A., et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023;29(5):1103–1112. - PMC - PubMed

Substances